Effect of an mGlu2/3 receptor antagonist on depressive behavior induced by withdrawal from chronic treatment with methamphetamine

Behavioural Brain Research

Volumn 246, Issue , 2013, Pages 24-28

  Iijima, Michihiko ^a   Koike, Hiroyuki ^a   Chaki, Shigeyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Depression; MGlu2 3 receptor; Nucleus accumbens; Psychostimulant withdrawal

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; METABOTROPIC RECEPTOR 2; METHAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; FORCED SWIMMING TEST; LOCOMOTION; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RECEPTOR BLOCKING; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

AMINO ACIDS; ANALYSIS OF VARIANCE; ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; IMMOBILITY RESPONSE, TONIC; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE WITHDRAWAL SYNDROME; SWIMMING; XANTHENES;

EID: 84875553685     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.02.039     Document Type: Article

References (26)

1. Barr A.M., Markou A., Phillips A.G. A 'crash' course on psychostimulant withdrawal as a model of depression. Trends in Pharmacological Sciences 2002, 23:475-482.
2. Chaki S., Ago Y., Palucha-Paniewiera A., Matrisciano F., Pilc A. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants. Neuropharmacology 2013, 66:40-52.
3. Chaki S., Yoshikawa R., Hirota S., Shimazaki T., Maeda M., Kawashima N., et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 2004, 46:457-467.
4. Cryan J.F., Hoyer D., Markou A. Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biological Psychiatry 2003, 54:49-58.
5. Di Chiara G., Loddo P., Tanda G. Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression. Biological Psychiatry 1999, 46:1624-1633.
6. 3 blockade. International Journal of Neuropsychopharmacology 2012, 15:429-434.
7. Feyissa A.M., Woolverton W.L., Miguel-Hidalgo J.J., Wang Z., Kyle P.B., Hasler G., et al. Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:279-283.
8. Grillon C., Cordova J., Levine L.R., Morgan C.A. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology 2003, 168:446-454.
9. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., Kallman M.J. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. Journal of Pharmacology and Experimental Therapeutics 1998, 284:651-660.
10. Karasawa J., Kotani M., Kambe D., Chaki S. AMPA receptor mediates mGlu 2/3 receptor antagonist-induced dopamine release in the rat nucleus accumbens shell. Neurochemistry International 2010, 57:615-619.
11. Karasawa J., Yoshimizu T., Chaki S. A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell. Neuroscience Letters 2006, 393:127-130.
12. Kenny P.J., Gasparini F., Markou A. Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. Journal of Pharmacology and Experimental Therapeutics 2003, 306:1068-1076.
13. Kingston A.E., Ornstein P.L., Wright R.A., Johnson B.G., Mayne N.G., Burnett J.P., et al. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology 1998, 37:1-12.
14. Koike H., Iijima M., Chaki S. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology 2011, 61:1419-1423.
15. Liechti M.E., Markou A. Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats. Biochemical Pharmacology 2007, 74:1299-1307.
16. Lin D., Koob G.F., Markou A. Time-dependent alterations in ICSS thresholds associated with repeated amphetamine administrations. Pharmacology Biochemistry and Behavior 2000, 65:407-417.
17. Markou A., Koob G.F. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 1991, 4:17-26.
18. Paterson N.E., Balfour D.J., Markou A. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. European Journal of Neuroscience 2007, 25:3099-3108.
19. Paulson P.E., Camp D.M., Robinson T.E. Time course of transient behavioral depression and persistent behavioral sensitization in relation to regional brain monoamine concentrations during amphetamine withdrawal in rats. Psychopharmacology 1991, 103:480-492.
20. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1997, Academic Press, San Diego. Compact 3rd ed.
21. Schlaepfer T.E., Cohen M.X., Frick C., Kosel M., Brodesser D., Axmacher N., et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 2008, 33:368-377.
22. Schoepp D.D., Wright R.A., Levine L.R., Gaydos B. Potter WZ LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003, 6:189-197.
23. Shirayama Y., Chaki S. Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Current Neuropharmacology 2006, 4:277-291.
24. Tatarczyńska E., Klodzińska A., Chojnacka-Wójcik E., Palucha A., Gasparini F., Kuhn R., et al. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. British Journal of Pharmacology 2001, 132:1423-1430.
25. Tremblay L.K., Naranjo C.A., Graham S.J., Herrmann N., Mayberg H.S., Hevenor S., et al. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Archives of General Psychiatry 2005, 62:1228-1236.
26. Witkin J.M., Monn J., Brittion T., Ornstein P., Li X., Johnson B.G. Further evidence for a metabotropic glutamate group II antagonist mechanism for the induction of antidepressant-like effects in rodents. Neuropsychopharmacology 2006, 31:S166.